BIOCYTOGEN-B (02315) saw its shares rise more than 7% in late trading. At the time of writing, the stock was up 7.06% to HK$61, with a turnover of HK$114 million. On the news front, on April 9, Sihuan Pharmaceutical and BIOCYTOGEN-B formally entered into a strategic cooperation agreement. The two parties will leverage BIOCYTOGEN-B's leading fully human antibody development platform, combined with Sihuan Pharmaceutical's extensive experience in drug development, production, and commercialization, to collaborate and exchange ideas on innovative drug research for various disease areas, including weight loss. Soochow Securities released a research note stating that BIOCYTOGEN-B's AI model is trained on vast, exclusive real antibody molecular data, continuously undergoing a cycle of "new data production - validation - AI evolution." This enables the screening of billions of fully human antibody sequences while ensuring high specificity and developability of candidate antibody drug sequences, thereby reducing subsequent R&D risks. The AI automation system is expected to accelerate the potential of the "Thousand Mice Ten Thousand Antibodies" program, building a highly efficient and scalable R&D and production system.
Comments